Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Antiviral Therapy
Topical gel inhibits HIV and HSV infection in cervicovaginal lavage fluid
March 17th, 2005
Mount Sinai School of Medicine researchers have demonstrated that a gel applied in the vagina provides protection from both the human immunodeficiency virus (HIV) and the herpes simplex virus (HSV). The study is the first to show that a gel can retain antiviral activity within the human vagina. It was funded by the U.S. National Institutes of Health (NIH) and investigated the efficacy of PRO 2000, a topical microbicide under development by Indevus Pharmaceuticals, Inc. "There is an urgent need for the development of safe and effective vaginal microbicides," Marla Keller, MD, assistant professor of Medicine at the Mount Sinai...
Source: Women's Health Weekly (2005-03-17)
|
